Dimerix

DMX-200 for Chronic Kidney Disease

Gold Coast Investment Showcase

20 June 2018

ASX: DXB

Disclaimer

Some of the information in this presentation may refer to Dimerix Limited ("Dimerix" or the "Company") based on information available to it as at the date of this presentation. The information in this presentation is provided in summary form and does not contain all information necessary to make an investment decision regarding Dimerix.

This presentation does not constitute an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any security in Dimerix, nor does it constitute financial product advice or take into account any individual's investment objectives, taxation situation, financial situation or needs. An investor must not act on the basis of any matter contained in this presentation but must make its own assessment of Dimerix and conduct its own investigations. Before making an investment decision, investors should consider the appropriateness of the information having regard to their own objectives, financial situation and needs, and seek legal, taxation and financial advice appropriate to their jurisdiction and circumstances. Dimerix is not licensed to provide financial product advice in respect of its securities or any other financial products. Cooling off rights do not apply to the acquisition of Dimerix securities.

Although reasonable care has been taken to ensure that the facts stated in this presentation are accurate and that the opinions expressed are fair and reasonable, no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. To the maximum extent permitted by law, none of Dimerix, its officers, directors, employees and agents, nor any other person, accepts any responsibility and liability for the content of this presentation including, without limitation, any liability arising from fault or negligence, for any loss arising from the use of or reliance on any of the information contained in this presentation or otherwise arising in connection with it.

The information presented in this presentation is subject to change without notice and Dimerix does not have any responsibility or obligation to inform you of any matter arising or coming to their notice, after the date of this presentation, which may affect any matter referred to in this presentation.

The distribution of this presentation may be restricted by law and you should observe any such restrictions.

Forward looking statements

This presentation contains certain forward looking statements that are based on the Company's management's beliefs, assumptions and expectations and on information currently available to management. Such forward looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results or performance of Dimerix to be materially different from the results or performance expressed or implied by such forward looking statements. Such forward looking statements are based on numerous assumptions regarding the Company's present and future business strategies and the political and economic environment in which Dimerix will operate in the future, which are subject to change without notice. Past performance is not necessarily a guide to future performance and no representation or warranty is made as to the likelihood of achievement or reasonableness of any forward looking statements or other forecast. To the full extent permitted by law, Dimerix and its directors, officers, employees, advisers, agents and intermediaries disclaim any obligation or undertaking to release any updates or revisions to information to reflect any change in any of the information contained in this presentation (including, but not limited to, any assumptions or expectations set out in the presentation).

Dimerix has 2 Phase 2 clinical trial programs starting recruiting in Q3 CY2018

1. DMX-200 for **Focal Segmental Glomerulosclerosis (FSGS)**
   - Phase 2a **US Orphan drug designation achieved - path to US drug registration**
   - **Reduced risk of adverse safety events** due to use of known molecules

2. DMX-200 for **Diabetic Kidney Disease (DKD)**
   - **Compelling data from recently completed Phase 2a** study for this more common disease

3. **"Receptor HIT" drug discovery platform**
   - Multiple further pipeline opportunities
   - Collaborative drug discovery and development opportunities

Note: FSGS and DKD are sub indications of Chronic kidney disease (CKD)

Corporate overview

Corporate snapshot

ASX code:	DXB#
Share price (13 June 18):	$0.105
Market cap:	$16.3m
Cash (30 Mar 2018):	$7.55m
Shares on issue*	155m

#Consolidation (20:1) completed 31st October 2017

*Unlisted Performance Shares: 3.75.m; Options (ESOP): 3.47m

Share price history

What is DMX-200?

- DMX-200 is an adjunct therapy. We administer two existing, well known drugs, to achieve a **synergistic effect**

- The two drugs used are:

  - **Propagermanium** – CCR2 antagonist with decades of use in Japan for chronic Hepatitis B

  - **Irbesartan** – existing standard of care, angiotensin receptor blocker. Irbesartan is a blood pressure medication

Dimerix has a granted patent (in the USA and elsewhere) over this method of treatment.

Chronic kidney disease (CKD)

- CKD is a growing global health problem affecting over 10% of the population
- Damaged kidneys “leak” proteins into the urine. This is called **proteinuria**.
- Proteinuria is the most common symptom of the disease and is the **strongest prognostic indicator** of disease progression
- Kidney disease generally gets progressively worse, with patients whose kidneys fail, **requiring dialysis or kidney transplant**

Current Treatments

- First line therapy is the use of drugs to reduce blood pressure, which can reduce proteinuria but do not stop progressive kidney failure

- In some types of kidney disease (eg FSGS), patients are given a cocktail of drugs including immunosuppressants and steroids such as prednisone, which have **poor side effects** and require **repeated treatment cycles**

- **There is a huge medical need for a safe treatment which can significantly reduce proteinuria and prolong the life of the kidney**

Will in remission



Relapse from nephrotic syndrome

Market value of lead clinical programs – DMX-200 for FSGS and DKD

Focal segmental glomerulosclerosis (FSGS)

- **FSGS** is a very serious disease and is characterized by **rapid progression to end-stage renal disease**
- DMX-200 has **US Orphan Drug Designation for FSGS**

Independent analysts estimate FSGS drug sales in the USA to be worth USD $1 billion per annum

Diabetic Kidney Disease (DKD)

- **DKD** is the single most common cause of CKD worldwide and is associated with significant increase in cardiovascular morbidity and mortality
- US prevalence is estimated as **3% of the population (9 million patients)**

The North American and global markets are expected to reach $1.3 billion and $2.9 billion in 2020 (respectively)

Sources: Persistence Market Research, Diabetic Nephropathy Market Report, 2015; Diabetes 2025 – U.S., state and metropolitan trends, Institute for Alternative Futures; Boyle et al. Projection of the year 2050 burden of diabetes in the U.S. adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence, Population Health Metrics, 2010, 8:29; Boer et al. Temporal trends in the prevalence of diabetic kidney disease in the U.S, JAMA. 2011; 305 (24): 2532-2539; www.cdc.gov/diabetes/statistics/prev/national/figpersons.htm

Market value – DMX-200

Comparable companies in the US with developments in FSGS are capitalised at more than $500 million

Compelling data for DMX-200 from the Phase 2a Trial

- When introduced, the current standard of care medication (irbesartan) was a step change in the treatment of chronic kidney disease patients
- In 2001 irbesartan was studied in a large group of type 2 diabetics. It was shown to reduce proteinuria levels by 24%
- Dimerix's 2017 Phase 2a study showed a further 35.6% reduction of proteinuria levels

Diabetic proteinuria mean reduction 35.6% n=10



* Paired, 2-way t-test

Our Phase 2a results represent a quantum leap in the way proteinuria levels can be managed. We are now moving into a further two Phase 2 studies to confirm our results in FSGS and DKD patients.

DMX-200: FSGS and DKD studies to be conducted in parallel

- Both trials are **randomised, double blind placebo-controlled, crossover studies**
- **"Crossover" trial design** means that **all** patients receive both placebo and DMX-200 on the trials, in randomised order
- These studies will investigate **A**T1R and **C**CR2 **T**argets for **I**nflammat**o**ry **N**ephrosis, and have been titled **ACTION**.
- **ACTION FOR FSGS:** Phase 2a trial will study the effects of DMX-200 in around 10 patients with FSGS - endpoints including safety and a number of efficacy (proteinuria reduction)
- **ACTION FOR DKD:** Phase 2b trial will study the effects of DMX-200 in around 40 patients with DKD - primary end point change in 24hr albumin creatinine ratio (ACR) based on identified patient responses in the Phase 2a study

DMX-200 Timelines

Completed activities

Activity	2015	2016	2017	H1 2018	H2 2018	H1 2019	H2 2019	2020
Phase 2a CKD "all comers" study								
FSGS + DKD CRO appointment, ethics submissions, lead site								
Phase 2a in FSGS								
Phase 2b in DKD								
Orphan Drug Designation	US			Europe				
Regulatory Authority engagement	US pre IND				European authority and US IND filing			
Intellectual Property	Australian patent	US patent	Japanese patent	Ongoing examination in Europe and new applications for dose and formulation				
Single pivotal FSGS Phase 3								
Licensing opportunities	FSGS, DKD, core patents							

Completed activities | Current development activities | Dimerix or partner future activities

Significant milestones

DMX-200 for FSGS and DKD

- ✓ **Ongoing** – Partnering discussions for FSGS and DKD
- ✓ **CY18Q2 –** Principal Investigator and CRO engaged for ACTION studies

- ❑ **CY18Q2 –** Ethics applications for ACTION studies
- ❑ **CY18Q3 –** Sites open and commencement of patient recruitment for ACTION studies
- ❑ **CY18Q3 –** European orphan drug application for FSGS (already granted in the US)
- ❑ **CY18Q4 –** European regulatory engagement for FSGS development path
- ❑ **CY19Q1 –** Commercial manufacturing data available for regulatory filings
- ❑ **CY19Q3 –** Preliminary ACTION for DKD data available
- ❑ **CY19Q4** – Preliminary ACTION for FSGS data available

DMX-200 Intellectual Property – a licencing opportunity

- Dimerix has **granted patents** in the **USA, Australia and Japan** covering our lead program DMX-200 (US patent no. 9,314,450); and pending applications in Europe and other major jurisdictions including
- The 9,314,450 patent covers the **use of CCR2 antagonists** in conjunction with, or sequential to, administration of **angiotensin receptor blockers** (ARBs), inclusive of treatment of CKD – **potentially a license opportunity to any company developing a CCR2 antagonist to be used with an ARB**
- Additional patent applications filed for formulation and dosage regimes for DMX-200
- The therapeutic use patent expires in **2032**


The United States of America

The Director of the United States Patent and Trademark Office

Has received an application for a patent for a new and useful invention. The title and description of the invention are enclosed. The requirements of law have been complied with, and it has been determined that a patent on the invention shall be granted under the law.

Therefore, this

United States Patent

Grants to the person(s) having title to this patent the right to exclude others from making, using, offering for sale, or selling the invention throughout the United States of America or importing the invention into the United States of America, and if the invention is a process, of the right to exclude others from using, offering for sale or selling throughout the United States of America, or importing into the United States of America, products made by that process, for the term set forth in 35 U.S.C. 154(a)(2) or (c)(1), subject to the payment of maintenance fees as provided by 35 U.S.C. 41(b). See the Maintenance Fee Notice on the inside of the cover.

David J. Kappos

Director of the United States Patent and Trademark Office

Dimerix receptor-HIT platform

Receptor-HIT

- Patented tool that enables understanding of receptor interactions
- Particularly suited to G-Protein Coupled Receptors (GPCRs) – most targeted receptor class for drug discovery
- Can identify **new uses** for existing drugs and drive the **discovery** of new drugs and research programs



Global pharmaceutical companies need access to Receptor-HIT technology to develop safe new drugs

Key takeaways – Dimerix Limited (ASX: DXB)

1. Strong track record in delivering regulatory, patent and clinical milestones

2. Two Phase 2 trials in kidney diseases about to commence, as a follow up to last year's Phase 2a trial, where compelling clinical data was seen

3. Significant market opportunity – across the areas of FSGS (orphan disease) and DKD

4. Funded to progress Phase 2 trials to significant inflection points

Contact

Kathy Harrison
Chief Executive Officer
+61 419 359 149
kathy.harrison@dimerix.com

Dimerix Limited
ACN 001 285 230
www.dimerix.com